Verified Nov 2026
Other
·

·
Since 1966
Lotus Pharmaceutical is a specialty pharmaceutical company founded in 1966 and based in Taiwan, with 1,000–5,000 employees and estimated revenue of $500 million to $1 billion. It develops generic and novel medicines for oncology, central nervous system, cardiovascular, and women's health markets across more than 90 countries. In August 2026, the company entered a licensing agreement with Alvotech to commercialize biosimilar candidates in the U.S. and selected Asian markets.
Lotus Pharmaceutical Co., Ltd at a glance
Revenue
$500M-1B
Est. band
Employees
1,000-5,000
Founded
1966
Industries
Automotive
Electric Vehicles
Medical
Industrial Equipment
Overview
Lotus Pharmaceutical is a specialty pharmaceutical company founded in 1966 and based in Taiwan, with 1,000–5,000 employees and estimated revenue of $500 million to $1 billion. It develops generic and novel medicines for oncology, central nervous system, cardiovascular, and women's health markets across more than 90 countries. In August 2026, the company entered a licensing agreement with Alvotech to commercialize biosimilar candidates in the U.S. and selected Asian markets.
At a glance
Attribute | Detail |
|---|---|
Founded | 1966 |
Employees | 1,000-5,000 |
Revenue | $500M-1B (estimated) |
What Lotus Pharmaceutical Co., Ltd makes
The company holds certifications from the U.S. FDA and EU EMA and manufactures oral anti-cancer drugs, oral formulations for central nervous system and cardiovascular conditions, and over-the-counter medicines.
Latest developments
2026-11-13 — Lotus Pharmaceutical Gets Board Nod for Up to $100 Million Financing Facility; Shares Down 9% | MarketScreener Hong Kong (marketscreener.com)
2026-11-12 — Lotus Pharmaceutical Reports Results for the First Nine Months of 2026 (lotuspharm.com)
2026-10-07 — Lotus Pharmaceutical Announces Completion of UroVaxom® Product Rights Acquisition in South Korea (lotuspharm.com)
2026-08-21 — Lotus Pharmaceutical Announces Licensing and Commercialization Agreement with Alvotech for Biosimilar Candidates to Durvalumab and Emicizumab in the U.S. and Selected Asian Markets (lotuspharm.com)
2026-05-18 — Boryung Begins Alimta Supply to Taiwan's Lotus, Expanding Global CDMO Business - Seoul Economic Daily (sedaily.com)
2026-04-02 — Lotus Pharmaceutical Announces Acquisition of Sandoz AG’s Philippines Business, Strengthening Its Presence in Southeast Asia (lotuspharm.com)
Facilities
Public sources reference the following locations:
Taiwan — lotuspharm.com
Geneva, Switzerland — lotuspharm.com
Company details
Lotus operates manufacturing and distribution facilities in Taiwan and Geneva, Switzerland, and maintains strategic partnerships to expand its capabilities across the Asia-Pacific region. Lotus Pharmaceutical Co., Ltd was founded in 1966, and has an estimated 1,000-5,000 employees.
Frequently asked questions
What does Lotus Pharmaceutical Co., Ltd do?
Lotus Pharmaceutical is a specialty pharmaceutical company founded in 1966 and based in Taiwan, with 1,000–5,000 employees and estimated revenue of $500 million to $1 billion. It develops generic and novel medicines for oncology, central nervous system, cardiovascular, and women's health markets across more than 90 countries. In August 2026, the company entered a licensing agreement with Alvotech to commercialize biosimilar candidates in the U.S. and selected Asian markets.
When was Lotus Pharmaceutical Co., Ltd founded?
Lotus Pharmaceutical Co., Ltd was founded in 1966.
How big is Lotus Pharmaceutical Co., Ltd?
Lotus Pharmaceutical Co., Ltd has an estimated 1,000-5,000 employees, with revenue in the $500M-1B range (estimated).
Related suppliers
Explore other suppliers in the LightSource directory:
Last verified Nov 2026. Is this your company? Request a correction.
Location & contact
Evaluating suppliers like these?
This profile is part of a public-data sample of the full LightSource directory. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.
